DMTTF News and Press, Small Pharma From 11/01/21

Company advances ongoing clinical trials with Phase I completed and dosing initiated in Phase IIa trial for lead product candidate, SPL026, a DMT-assisted therapy for the treatment of Major Depressive Disorder Fast-track Innovation Passport Designation awarded by the MHRA ...

LONDON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announced that it has received European patent gra...

LONDON, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce that following discussions with t...

LONDON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “ Company ” or “ Small Pharma ”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce its successful upgrade from the O...

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations PR Newswire NEW YORK , Oct. 18, ...

KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th Psychedelic and CNS Company Executives share vision, answer questions live at VirtualInvestor...

Small Pharma To Present At Canaccord Genuity's Annual Growth Conference Progress in the development of DMT-assisted therapy for the treatment of depression Canada NewsWire LONDON , Aug. 9, 2021 /CNW/ -- Small Pharma Inc. (TSXV: DMT) (the " Company " o...